GOG FOUNDATION- GOG-3103/Trofuse-022 MK-2870-022
Trial Overview
Official Title
A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer
Study Purpose
To test the safety, efficacy, and effect on quality of life of sac-TMT when given alone, with bevacizumab, or compared to no maintenance treatment.
Diagnosis
High or low grade epithelial ovarian cancer (serous, endometrioid, carcinosarcoma, clear cell)Eligibility
First recurrence of platinum sensitive ovarian cancer
Intervention
Sacituzumab tirumotecan +/- bevacizumab VS. bevacizumab alone
For more information, click the link below:
https://clinicaltrials.gov/study/NCT06824467?term=GOG-3103&rank=1
Key Participation Requirements
Trial Location(s)
Gender
Female
Age
19 years and older
Enrollment Status
Recruiting
Phase
Phase III
Methodist Health System Trial Code
GOG-3103